Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Methyclothiazide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 1.00 |
| ▸ | ADRA1A | P35348 | 1/20 | 1.00 |
| ▸ | CA7 | P43166 | 3/20 | 0.56 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.54 |
| ▸ | LMNA | P02545 | 7/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | HTT | P42858 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 1/20 | 0.49 |
| ▸ | CA4 | P22748 | 1/20 | 0.49 |
| ▸ | CA6 | P23280 | 1/20 | 0.49 |
| ▸ | CA5A | P35218 | 1/20 | 0.49 |
| ▸ | CA9 | Q16790 | 1/20 | 0.49 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.49 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.47 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Methyclothiazide SCHEMBL27178 | 1.00 | CHRM1 (1.00) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL49396 | 1.00 | CHRM1 (1.00) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL8051136 | 1.00 | CHRM1 (1.00) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL8065909 | 1.00 | CHRM1 (1.00) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL1819665 | 1.00 | CHRM1 (1.00) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL5450863 | 0.89 | CHRM1 (0.79) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methyclothiazide SCHEMBL10380303 | 0.88 | CHRM1 (0.77) | CHRM1ADRA1ACA7TDP1LMNA | |
| Polythiazide SCHEMBL6929926 | 0.87 | CHRM1 (0.76) | CHRM1ADRA1ACA7TDP1LMNA | |
| Methalthiazide SCHEMBL28279774 | 0.87 | CHRM1 (0.76) | CHRM1ADRA1ACA7TDP1LMNA | |
| SCHEMBL14394546 | 0.86 | CHRM1 (0.75) | CHRM1ADRA1ACA7TDP1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025050228-A1 | PHARMACEUTICAL COMPOSITION COMPRISING A PEPTIDE OR A COMBINATION OF PEPTIDES AGONISTIC TO THE MAS, AT1 AND AT2 RECEPTORS | PONTIFICIA UNIVERSIDAD CATÓLICA DE CHILE (CL) | 2025-03-13 | — | — | WO | claimed |
| WO-2026090360-A1 | FUSED PYRIMIDINE COMPOUNDS FOR TREATMENT OF TINNITUS, HEARING LOSS, AND MENIERE'S DISEASE | OVID THERAPEUTICS INC. (US) | 2026-04-30 | — | — | WO | disclosed |
| EP-3565808-B1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX INC (US) | 2026-03-04 | — | — | EP | disclosed |
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-12-04 | — | — | US | disclosed |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2025-12-04 | — | — | US | disclosed |
| EP-4644498-A1 | COMPOSITION, COATING, WATER-RESISTANT BASE MATERIAL, AND METHOD FOR PRODUCING WATER-RESISTANT BASE MATERIAL | Maxell, Ltd. (JP) | 2025-11-05 | — | — | EP | disclosed |
| US-12454520-B2 | Protein degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2025-10-28 | — | — | US | disclosed |
| US-20250288650-A1 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | SPITFIRE PHARMA LLC (US) | 2025-09-18 | — | — | US | disclosed |
| EP-4611792-A1 | THERAPEUTIC REGIMENS AND METHODS FOR TREATMENT OF CARDIOVASCULAR RISK FACTORS USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4587045-A2 | THERAPEUTIC REGIMENS AND METHODS FOR REDUCING BODY WEIGHT IN A SUBJECT WITH FATTY LIVER DISEASE USING A GLP-1R AND GCGR AGONIST | Spitfire Pharma LLC (US) | 2025-07-23 | — | — | EP | disclosed |
| US-20230031776-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2023-02-02 | — | — | US | disclosed |
| EP-4106796-A1 | GLP-1R AND GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | Spitfire Pharma LLC (US) | 2022-12-28 | — | — | EP | disclosed |
| US-20220306610-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | ARDELYX, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| EP-4058029-A1 | MULTIMODAL COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-21 | — | — | EP | disclosed |
| EP-4051235-A1 | PRODRUG COMPOSITIONS AND METHODS OF TREATMENT | Aquestive Therapeutics, Inc. (US) | 2022-09-07 | — | — | EP | disclosed |
| WO-2022178366-A1 | GLP-1R, GIP-R AND/OR GCGR AGONISTS, FORMULATIONS, AND METHODS OF USE | SPITFIRE PHARMA LLC (US) | 2022-08-25 | — | — | WO | disclosed |
| WO-2022125598-A1 | THERAPEUTIC REGIMENS AND METHODS FOR LOWERING BLOOD GLUCOSE AND OR BODY WEIGHT USING GLP-1R AND GCGR BALANCED AGONISTS | SPITFIRE PHARMA LLC (US) | 2022-06-16 | — | — | WO | disclosed |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | ARDELYX, INC. (US) | 2022-05-03 | — | — | US | disclosed |
| US-20220062378-A1 | METHODS OF TREATING OR INHIBITING ONSET OF HUNTINGTON'S DISEASE | UNIVERSITY OF COPENHAGEN (DK) | 2022-03-03 | — | — | US | disclosed |
| WO-2022020756-A1 | COMPOSITIONS AND METHODS FOR TREATING PAIN AND ANXIETY DISORDERS | MANSELL JOHN (US) | 2022-01-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250288650-A1 | Therapeutic Regimens and Methods for Reducing Body Weight and/or Serum Lipids using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | CHRM1 1698/4885ADRA1A 251/4885CA7 4440/4885 |
| US-20250367263-A9 | Therapeutic Regimens and Methods for Treatment of Cardiovascular Risk Factors using a GLP-1R and GCGR Agonist | GLP1R, GCGR, GIPR | CHRM1 3470/4885ADRA1A 494/4885CA7 4864/4885 |
| US-20220306610-A1 | COMPOUNDS USEFUL FOR TREATING GASTROINTESTINAL TRACT DISORDERS | SLC10A2, FABP2, SLC10A1 | CHRM1 1298/4885ADRA1A 256/4885CA7 3704/4885 |
| US-20230031776-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | CHRM1 1878/4885ADRA1A 563/4885CA7 2489/4885 |
| US-12454520-B2 | Protein degraders and uses thereof | MDM2, CUL1, PSMG3 | CHRM1 4873/4885ADRA1A 4696/4885CA7 4189/4885 |
| US-11318129-B2 | Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders | SLC10A1, SLC10A2, FABP3 | CHRM1 1878/4885ADRA1A 563/4885CA7 2489/4885 |
| US-20250367188-A1 | COMPOUNDS AND METHODS FOR INHIBITING NHE-MEDIATED ANTIPORT IN THE TREATMENT OF DISORDERS ASSOCIATED WITH FLUID RETENTION OR SALT OVERLOAD AND GASTROINTESTINAL TRACT DISORDERS | SLC10A1, SLC10A2, FABP3 | CHRM1 1878/4885ADRA1A 563/4885CA7 2489/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.